EVAS THERAPEUTICS, LLC.

Basic Information

613 HUNTLEY HEIGHTS DRIVE
BALLWIN, MO, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 143727191
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Novel antithrombotic agents to prevent hemodialysis vascular access failure

    Amount: $1,365,616.00

    DESCRIPTION (provided by applicant): Currently, more than 60 % of end-stage renal diseases patients who require chronic hemodialysis are accessed through a native arteriovenous fistula (AVF) or synthe ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Pharmacologic treatment of thromboembolism

    Amount: $167,481.00

    DESCRIPTION (provided by applicant): Thromboembolic disorders are major causes of morbidity and mortality in the Western societies. Anticoagulants are pivotal agents in the prevention and treatment of ...

    SBIR Phase I 2009 Department of Health and Human Services
  3. Novel Recombinant Anticoagulant Proteins

    Amount: $152,652.00

    DESCRIPTION (provided by applicant): Phase I: Clot formation in the blood vessel (thrombosis) causes a broad range of serious clinical conditions, such as unstable angina, acute myocardial infarction, ...

    SBIR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government